[Azithromycin: new orientations].
Coulaud
J P
JP
Institut de Médecine et d'Epidémiologie Africaines, Fondation Léon-MBA, Paris, France.
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D003457:Cryptosporidiosis / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D016778:Malaria, Falciparum / Q000188:drug therapy*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy; D010963:Plasmodium falciparum / Q000187:drug effects; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy; D016781:Toxoplasmosis, Cerebral / Q000150:complications / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D017963:Azithromycin
L'azithromycine: nouvelles orientations.